A previous study has shown a connection between the major histocompatibility complex (MHC) class II allele HLA-DRB1*1501 (dominant haplotype of northern Europe) and the risk of MS by threefold. This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.